Abstracts tagged "treatment and ultrasonography"

Abstract Number: 1137 • 2017 ACR/ARHP Annual Meeting
Urate Lowering to ACR-Recommended Targets Allows Significant Improvement of Severe Gout: A Monocentric Prospective Trial in Vietnam, Using a Systematic Treatment Protocol
Thomas Bardin^1,2,3, Quang Nguyen Dinh¹, Khoi Tran Minh¹, Nghia Le Hieu¹, Minh Do Duc⁴, Pascal Richette^5,6 and Matthieu Resche-Rigon^3,7, ¹French-Vietnamese Gout Research Center, Ho Chi Minh City, Viet Nam, ²Rheumatology, Hôpital Lariboisière, Paris, France, ³Université Paris Diderot, Paris, France, ⁴Molecular Biology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam, ⁵Rhumatologie, Hôpital Lariboisière, Paris, France, ⁶Rheumatology Department, Université Paris Diderot, Paris, France, ⁷Biostatistics, Hôpital Saint-Louis, Paris, France
Background/Purpose: Gout is frequent and severe in Vietnam, where urate-lowering drugs (ULD) are seldom used and many patients are treated only with traditional herbal medicine.…
Abstract Number: 2938 • 2017 ACR/ARHP Annual Meeting
Is Synovial Hypertrophy without Doppler Activity in Rheumatoid Arthritis Joints Sensitive to Change ? – Results of a Longitudinal Ultrasound Study
Lene Terslev¹, Mikkel Østergaard¹, Joseph Sexton² and Hilde B Hammer², ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Ultrasound (US) is used to assess diseases activity in rheumatoid arthritis (RA). Gray scale (GS) US shows the synovial hypertrophy (SH) and Doppler the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].